Follitropin alfa biosimilar - Allergan/Itero Biopharmaceuticals

Drug Profile

Follitropin alfa biosimilar - Allergan/Itero Biopharmaceuticals

Alternative Names: Follicle stimulating hormone biosimilar - Actavis/Itero Biopharmaceuticals; rFSH biosimilar - Actavis/Itero Biopharmaceuticals

Latest Information Update: 03 Apr 2017

Price : $50

At a glance

  • Originator Itero Biopharmaceuticals
  • Developer Allergan; Itero Biopharmaceuticals
  • Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Female infertility

Most Recent Events

  • 26 Nov 2015 Phase-III clinical trials in Female infertility in United Kingdom (SC) (EudraCT2013-003788-67)
  • 01 Aug 2014 Phase-III clinical trials in Female infertility in Austria, Belgium and Spain (SC) (EudraCT2013-003788-67)
  • 31 Jan 2014 Phase-III clinical trials in Female infertility in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top